<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336301">
  <stage>Registered</stage>
  <submitdate>1/12/2010</submitdate>
  <approvaldate>6/12/2010</approvaldate>
  <actrnumber>ACTRN12610001069044</actrnumber>
  <trial_identification>
    <studytitle>Topical timolol maleate gel for non-complicated superficial infantile haemangiomas</studytitle>
    <scientifictitle>Topical timolol maleate gel for the reduction in colour and size of non-complicated superficial infantile haemangiomas.</scientifictitle>
    <utrn>U1111-1118-3598</utrn>
    <trialacronym />
    <secondaryid>n/a</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infantile haemangioma</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Timolol maleate gel 0.5%  one drop applied to the cutaneous ,small (&lt;5cm), superficial infantile haemangioma twice daily for 24 weeks</interventions>
    <comparator>Emollient lubricant eye drop one drop applied to the cutaneous small (&lt;5cm), superficial infantile haemangioma twice daily for 24 weeks. Placebo chosen as drops feel the same as the active gel.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>decrease in red colour scored 0,1,2 both clinically and from photographs</outcome>
      <timepoint>1 week,2 weeks,4 weeks,8weeks,12 weeks,16 weeks,20 weeks,24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>heart rate - with a stethescope measure beats per minute</outcome>
      <timepoint>1 week,2 weeks,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>blood pressure- with a sphygmomanometer</outcome>
      <timepoint>1 week,2 weeks,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>infantile haemangiomas &lt;5 cm</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>PHACE syndrome
lesions &gt;5cm diametre
deep subcutaneous lesions
&lt;5 weeks old
&gt;24 weeks old</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>randomisation using adaptive allocation of minimisation to ensure randomisation of subgroups 5-14 weeks and 15-24 weeks. allocation concealment with randomisation will be carried out by the pharmacist with the assistance of the statistician.</concealment>
    <sequence>pharmacist will phone the statistician with the subgroup age 5-14 weeks versus 15-24 weeks  to ensure stratified allocation and the allocation will be generated using permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/02/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney Children's Hospital</primarysponsorname>
    <primarysponsoraddress>High St
Randwick
NSW 2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Sydney children's Hospital foundation</fundingname>
      <fundingaddress>High st 
Randwick
NSW 2031</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Non-complicated infantile haemangiomas have been followed up with minimal intervention because of spontaneous involution. However the involution phase is slow and most children go to school with a disfiguring infantile haemangioma. Propranolol has been observed to accelerate the involution phase and a small retrospective chart review and a single case report have suggested that topical timolol maleate gel 0.5% may reduce the proliferative phase of smal and superficial infantile haemangiomas with reduced systemic complications.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SESI NSW Health Northern Hospital network</ethicname>
      <ethicaddress>edmund Blacket Building
The prince of wales Hospital
Cnr High and Avoca Sts
Randwick
NSW2031</ethicaddress>
      <ethicapprovaldate>23/11/2010</ethicapprovaldate>
      <hrec>1/10/0116</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>as above</name>
      <address>as above</address>
      <phone>as above</phone>
      <fax>as above</fax>
      <email>orli.wargon@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Orli Wargon</name>
      <address>Department of Paediatric dermatology
High st 
Randwick
NSW 2031</address>
      <phone>+61 2 93821776</phone>
      <fax>+61 2 93821787</fax>
      <email>fenella.brisley@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>as above</name>
      <address>as above</address>
      <phone>as above</phone>
      <fax>as above</fax>
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>